Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

Inclusion criteria : * 18 to 65 years old. * Type 2 diabetes patients insufficient controlled by 1-3 oral anti-hyperglycemic drugs (OADs) with stable dose at least 3 months: * If on 1 OAD, provided with the following doses (including but not limited to): * α-glucosidase inhibitor: 100mg, three times a day (tid); * metformin: 1.5-2.0 g/day; * sulphonylureas: sub-maximum (half dose above) to maximum tolerated dose; * thiazolidinediones: eg. pioglitazone, 30-40 mg/day. * Besides the medications listed above, if on 1 OAD, others should be maximum tolerated dose allowed in package insert. * If on 2-3 OADs, any range of dose is acceptable. * HbA1c \>7%, and ≤10.5%. * FPG \>7 mmol/L. * Body mass index (BMI) ≥20 kg/m\^2, and ≤40 kg/m\^2. * Diabetes duration ≥1 year. * Physician decides to and the patient is willing to start basal insulin (BI) treatment. * Willing to join the study and sign the informed consent. Exclusion criteria: * Type 1 diabetes patients. * Patients with acute diabetic complications (including unexplained severe hypoglycemia in the last 6 months). * Previous treatment with insulin for more than 1 month cumulatively in last 1 year, or treatment with insulin in the last 3 months before the screening. * Known hypoglycemia unawareness or recurrent hypoglycemia. * Hypersensitivity to study drug or its excipients. * Any clinically significant acute major organ or systemic disease, or any other situation judged by the Investigator, that is difficult for the 24 weeks follow-up. * Pregnancy or breastfeeding women. * Have any mental disorders, lack self-control or not able to express accurately. * Involved in another clinical trial simultaneously or within a 1 month before start of trial. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.